Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martina Sanlorenzo

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
Wiener Medizinische Wochenschrift (1946)|January 17, 2017
Update on advanced melanoma treatments: small molecule targeted therapy, immunotherapy, and future combination therapiesAndrew Kwong, Martina Sanlorenzo, Klemens Rappersberger, et al.
Clinical, Cosmetic and Investigational Dermatology|September 9, 2015
Melanoma risk perception and prevention behavior among African-Americans: the minority melanoma paradoxAlina Goldenberg, Igor Vujic, Martina Sanlorenzo, et al.
Melanoma Management|September 8, 2018
New insights in melanoma biomarkers: long-noncoding RNAsRicardo Moreno-Traspas, Igor Vujic, Martina Sanlorenzo, et al.
Journal of the American Academy of Dermatology|July 31, 2016
The infliximab biosimilar in the treatment of moderate to severe plaque psoriasisPaolo Dapavo, Igor Vujic, Maria Teresa Fierro, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|March 3, 2017
Etanercept, Adalimumab und Ustekinumab bei Psoriasis: Analyse von 209 Behandlungsreihen in ÖsterreichLeo Richter, Igor Vujic, Alma Sesti, et al.
Oncotarget|November 9, 2018
MEK/CDK4,6 co-targeting is effective in a subset of NRAS, BRAF and 'wild type' melanomasChristian Posch, Martina Sanlorenzo, Jeffrey Ma, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|February 28, 2017
Etanercept, adalimumab, and ustekinumab in psoriasis: analysis of 209 treatment series in AustriaLeo Richter, Igor Vujic, Alma Sesti, et al.
The Journal of Investigative Dermatology|May 11, 2016
Searching for the Chokehold of NRAS Mutant MelanomaChristian Posch, Igor Vujic, Babak Monshi, et al.
Melanoma Research|August 22, 2022
Melanoma risk during immunomodulating treatmentYixuan James Zheng, Wilson Ho, Martina Sanlorenzo, et al.
Oncotarget|June 21, 2016
Pharmacological inhibitors of c-KIT block mutant c-KIT mediated migration of melanocytes and melanoma cells in vitro and in vivoChristian Posch, Homayoun Moslehi, Martina Sanlorenzo, et al.
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
Wiener Medizinische Wochenschrift (1946)|January 17, 2017
Update on advanced melanoma treatments: small molecule targeted therapy, immunotherapy, and future combination therapiesAndrew Kwong, Martina Sanlorenzo, Klemens Rappersberger, et al.
Clinical, Cosmetic and Investigational Dermatology|September 9, 2015
Melanoma risk perception and prevention behavior among African-Americans: the minority melanoma paradoxAlina Goldenberg, Igor Vujic, Martina Sanlorenzo, et al.
Melanoma Management|September 8, 2018
New insights in melanoma biomarkers: long-noncoding RNAsRicardo Moreno-Traspas, Igor Vujic, Martina Sanlorenzo, et al.
Journal of the American Academy of Dermatology|July 31, 2016
The infliximab biosimilar in the treatment of moderate to severe plaque psoriasisPaolo Dapavo, Igor Vujic, Maria Teresa Fierro, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|March 3, 2017
Etanercept, Adalimumab und Ustekinumab bei Psoriasis: Analyse von 209 Behandlungsreihen in ÖsterreichLeo Richter, Igor Vujic, Alma Sesti, et al.
Oncotarget|November 9, 2018
MEK/CDK4,6 co-targeting is effective in a subset of NRAS, BRAF and 'wild type' melanomasChristian Posch, Martina Sanlorenzo, Jeffrey Ma, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|February 28, 2017
Etanercept, adalimumab, and ustekinumab in psoriasis: analysis of 209 treatment series in AustriaLeo Richter, Igor Vujic, Alma Sesti, et al.
The Journal of Investigative Dermatology|May 11, 2016
Searching for the Chokehold of NRAS Mutant MelanomaChristian Posch, Igor Vujic, Babak Monshi, et al.
Melanoma Research|August 22, 2022
Melanoma risk during immunomodulating treatmentYixuan James Zheng, Wilson Ho, Martina Sanlorenzo, et al.
Oncotarget|June 21, 2016
Pharmacological inhibitors of c-KIT block mutant c-KIT mediated migration of melanocytes and melanoma cells in vitro and in vivoChristian Posch, Homayoun Moslehi, Martina Sanlorenzo, et al.
Pageof 5